Company Info

Number of Employees

16,000

Ticker

LONN (SWX)

Revenue

$1,000.0

Visit Website

Lonza

CDMO

Tagline

Enabling a Healthier World

Overview

At Lonza, we enable a healthier world by supporting our healthcare customers on the path to commercialization. Our community of 16,000 skilled employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech, and nutrition markets. By combining technological insight with world-class manufacturing, scientific expertise, and process excellence, we help our customers to deliver new and innovative medicines that help treat a wide range of diseases.

Company Services

Services/CapabilitiesCDMO

+ Biologic Manufacturing Capacities

Scale

+ Biomanufacturing

cGMP Microbial Manufacturing
Vaccine Development & Manufacturing

+ Development Services

Analytical Development & Validation
Bioanalytical Services
Process Development & Validation
Scale Up/Tech Transfer
Stability Testing

+ Drug Product Manufacturing

Cytotoxic / High Potency Compounds (OEL < 1µg/m3)
Lyophilized Products Manufacturing
Sterile Bags Manufacturing

+ Drug Substance Manufacturing

Cytotoxic / High Potency Compounds (OEL < 1µg/m3)

+ Packaging

Carton Packaging
Prefilled Syringes/Cartridges/Pen Devices

Company Info

Lonza

Tagline

Overview

Company Services

Services/CapabilitiesCDMO

Contributions

In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?

What do you consider the biggest challenge that the pharma/biopharma industry currently faces?

Tuning the Myeloid Compartment with a Best-in-Class CDMO

Q: What’s the key to being a leader in the industry?

Q: What important company milestone do you anticipate reaching in 2022?

Innovating in Automation and Data Management to Advance Microbiology

Advancing Drug Development with Emerging Technologies

Q: What do you see as the key innovations or technologies that will make personalized/precision medicine a reality?

Q: For what therapeutic area do you think we will see the greatest progress in the coming years?

A Small Biotech with Two Complex Bispecific Antibody Candidates Benefits from Lonza’s Blend of Expertise and Flexibility